Tectonic Therapeutic Inc (TECX)
Tectonic Therapeutic, Inc. is a biotechnology company listed on the NASDAQ under the ticker TECX. The company focuses on discovering and developing therapeutic proteins and antibodies designed to modulate the activity of G protein coupled receptors, or GPCRs. Its GEODe technology platform is intended to support the identification and development of GPCR-targeted biologic medicines. Tectonic’s lead program is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, a GPCR target associated with the hormone relaxin. The pipeline also includes TX2100 for hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for fibrosis, and additional GPCR modulator candidates. The company is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TECX
|
$26.20
|
-1.1% Downside
|
Fair
|
$76.63
|
189.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
2.3x
|
518.1 M
|
297.9 M
|
0.8%
|
60.9%
|
22.7
|
84.4%
|
